NEFL and Alzheimer disease: Ultrasensitive immunological assays and MS-based methods can quantify the plasma concentrations of NfL and offer important information on the neurodegenerative processes occurring in the patient’s brain, which, combined with more specific biomarkers for AD, can help in diagnosing even preclinical cases.